Bristol Myers' Mavacamten Shows Sustained Improvements In Cardiovascular Outcomes In Cardiomyopathy Study

Bristol Myers Squibb Co BMY announced new interim results from the EXPLORER-LTE cohort of the MAVA-LTE study of mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (obstructive HCM). 

• The data exhibited sustained improvements in cardiovascular outcomes at 48 and 84 weeks.
• EXPLORER-LTE enrolled 231 patients. 
• The safety profile remained consistent with EXPLORER-HCM. No new safety signals were observed during longer-term follow-up, and the exposure adjusted event rates were stable or lower in this cohort.
• Related: Bristol Myers Squibb's Mavacamten Aces Late-Stage Trial In Cardiomyopathy.
• The resting LVOT gradient decreased from baseline by -35.6 mmHg ± 32.6 mmHg at Week 48. Similar reductions persisted throughout this extension period (up to 84 weeks).
• Similarly, Valsalva LVOT gradient decreased from baseline by -45.3 mmHg ± 35.9 mmHg at Week 48. Sustained efficacy persisted throughout this extension period (up to 84 weeks).
• Serum NT-proBNP levels decreased from baseline by a median of -480 ng/L at Week 48. Similar reductions persisted throughout this extension period (up to 84 weeks).
• Resting LVEF decreased from baseline by -7.0% ± 8.3% at Week 48. A similar level of reduction persisted throughout this extension period (up to 84 weeks).
• Price Action: BMY shares closed 0.96% lower at $73.11 during after-hours trading on Friday.